Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo

FEMS Immunology and Medical Microbiology

Volumn 62, Issue 1, 2011, Pages 11-22

  Little, Stephen F ^a   Webster, Wendy M ^a   Fisher, Diana E ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax lethal toxin; Antibody dependent enhancement; in vivo; Monoclonal antibodies

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL TOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10D2; MONOCLONAL ANTIBODY 10E10; MONOCLONAL ANTIBODY 10G4; MONOCLONAL ANTIBODY 10G8; MONOCLONAL ANTIBODY 11D2; MONOCLONAL ANTIBODY 12G8; MONOCLONAL ANTIBODY 13C7; MONOCLONAL ANTIBODY 14B7; MONOCLONAL ANTIBODY 18C2; MONOCLONAL ANTIBODY 1C5; MONOCLONAL ANTIBODY 1G3; MONOCLONAL ANTIBODY 1G7; MONOCLONAL ANTIBODY 2C11; MONOCLONAL ANTIBODY 2D3 1; MONOCLONAL ANTIBODY 2D3 3; MONOCLONAL ANTIBODY 2D5; MONOCLONAL ANTIBODY 2F7; MONOCLONAL ANTIBODY 2F9; MONOCLONAL ANTIBODY 3B6; MONOCLONAL ANTIBODY 3C5; MONOCLONAL ANTIBODY 3D2; MONOCLONAL ANTIBODY 3F10; MONOCLONAL ANTIBODY 3F3; MONOCLONAL ANTIBODY 6C3; MONOCLONAL ANTIBODY 9D11; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT ENHANCEMENT; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; MACROPHAGES; MALE; MICE; RATS; RATS, INBRED F344;

EID: 79955003814     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00782.x     Document Type: Article

References (60)

1. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR & Harris E (2010) Lethal antibody enhancement of Dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
2. Beall FA, Taylor MJ & Thorne CB (1962) Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol 83: 1274-1280.
3. Belova EV, Dubileî SA, Kravchenko TB, Kolesnikov AV, Zakharova MIu & Shemiakin IG (2004) Monoclonal antibodies to B. anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro. Mol Gen Mikrobiol Virusol 3: 21-26.
4. Brossier F, Lévy M, Landier A, Lafaye P & Mock M (2004) Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 72: 6313-6317.
5. Dejnirattisai W, Jummainsong A, Onsirisakul N et al. (2010) Cross-reacting antibodies enhance Dengue virus infection in humans. Science 328: 745-748.
6. Duesbery NS, Webb CP, Leppla SH et al. (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737.
7. Ezzell JW, Ivins BE & Leppla SH (1984) Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun 45: 761-767.
8. Friedlander AM (1986) Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 261: 7123-7126.
9. Gimenez HB, Chisholm S, Dornan J & Cash P (1996) Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin Diagn Lab Immun 3: 280-286.
10. Goncalvez AP, Engle RE, St.Claire M, Purcell RH & Lai C-J (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. P Natl Acad Sci USA 104: 9422-9429.
11. Green BD, Battisti L, Koehler TM, Thorne CB & Ivins BE (1985) Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 49: 291-297.
12. Gubbins MJ, Berry JD, Corbett CR, Mogridge J, Yuan XY, Schmidt L, Nicolas B, Kabani A & Tsang RS (2006) Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Mic 47: 436-443.
13. Guillon C, Schutten M, Boers PHM, Gruters RA & Osterhaus ADME (2002) Antibody-mediated enhancement of human immunodeficiency virus Type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J Virol 76: 2827-2834.
14. Gupta PK, Moayeri M, Crown D, Rattah RJ & Leppla SH (2008) Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One 3: e3130.
15. Haines BW, Klein F & Lincoln RE (1965) Quantitative assay for crude anthrax toxins. J Bacteriol 89: 74-83.
16. Hansen MB, Nielsen SE & Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210.
17. Homsy J, Meyer M & Levy JA (1990) Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 64: 1437-1440.
18. Huisman W, Martina BEE, Rimmelzwaan GF, Gruters RA & Osterhaus ADME (2009) Vaccine-induced enhancement of viral infections. Vaccine 27: 505-512.
19. Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ & Russell SJ (2006) Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80: 8530-8540.
20. Ivins BE, Welkos SL, Little SF, Crumrine MH & Nelson GO (1992) Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 60: 662-668.
21. Jernigan DB, Raghunathan PL, Bell BP et al. (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8: 1019-1028.
22. Kelly-Cirino CD & Mantis NJ (2009) Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 77: 4859-4867.
23. Keppie J, Harris-Smith PW & Smith H (1963) The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action. Brit J Exp Pathol 44: 446-453.
24. Kuo S-R, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang W-J & Frankel AE (2008) Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathogenesis 44: 467-472.
25. Leppla SH (1982) Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. P Natl Acad Sci USA 79: 3162-3166.
26. Leppla SH (1996) Anthrax toxins. Handbook of Natural Toxins, vol 8, Bacterial Toxins and Virulence Factors in Disease (Moss J, Iglewski B, Vaughn M & Tu AT, eds), pp. 543-572. Marcel Dekker Inc., New York.
27. Lidbury BA & Mahalingam S (2000) Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 74: 8376-8381.
28. Little SF, Leppla SH & Cora E (1988) Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56: 1807-1813.
29. Little SF, Leppla SH & Friedlander AM (1990) Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun 58: 1606-1613.
30. Little SF, Leppla SH, Burnett JW & Friedlander AM (1994) Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem Bioph Res Co 199: 676-682.
31. Little SF, Novak JM, Lowe JR, Leppla SH, Singh Y, Klimpel KR, Lidgerding BC & Friedlander AM (1996) Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142: 707-715.
32. Little SF, Ivins BE, Fellows PF & Friedlander AM (1997) Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 65: 5171-5175.
33. Little SF, Ivins BE, Fellows PF, Pitt MLM, Norris SLW & Andrews GP (2004a) Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22: 422-430.
34. Little SF, Webster WM, Norris SLW & Andrews GP (2004b) Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice. Biologicals 32: 62-69.
35. Mehlhop E, Ansarah-Sobrinho C, Johnson S, Engle M, Fremont DH, Pierson TC & Diamond MS (2007) C1q inhibits antibody-dependent enhancement of flavivirus infection in vitro and in vivo in an IgG subclass specific manner. Cell Host Microbe 2: 417-426.
36. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A & Yampolskaya O (1994) The Sverdlovsk anthrax outbreak of 1979. Science 266: 1202-1208.
37. Mikesell P, Ivins BE, Ristroph JD & Dreier TM (1983) Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun 39: 371-376.
38. Moayeri M, Martinez NW, Wiggins J, Young HA & Leppla SH (2004) Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun 72: 4439-4447.
39. Mohamed N, Li J, Ferreira CS, Little SF, Friedlander AM, Spitalny GL & Castelo CS (2004) Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 72: 3276-3283.
40. Ochiai H, Kurokawa M, Matsui S, Yamamoto T, Kuroki Y, Kishimoto C & Shiraki K (1992) Infection enhancement of influenze A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J Med Virol 36: 217-221.
41. Pitt MLM, Little SF, Ivins BE, Fellows P, Barth J, Hewetson JGP, Dertzbaugh M & Friedlander AM (2001) In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19: 4768-4773.
42. Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, Kobiler D, Shafferman A & Velan B (2001) Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69: 2888-2893.
43. Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, Collier RJ, Dadachova E & Casadevall A (2006) A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 74: 4149-4156.
44. Robinson WE Jr, Montefiori DC & Mitchell WM (1988) Antibody-dependent enhancement of human immunodeficiency virus Type1 infection. Lancet 1: 790-794.
45. Staats HF, Alam SM, Scearce RM, Kirwan SM, Zhang JX, Gwinn WM & Haynes BF (2007) In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun 75: 5443-5452.
46. Takada A & Kawaoka Y (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13: 387-398.
47. Takada A, Tuazon CU & Ennis FA (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242: 580-583.
48. Takada A, Watanabe S, Okazaki K, Kida H & Kawaoka Y (2001) Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol 75: 2324-2330.
49. Takada A, Feldmann H, Ksiazek TG & Kawaoka Y (2003) Antibody-dependent enhancement of Ebola virus infection. J Virol 77: 7539-7544.
50. Tirado SMC & Yoon K-J (2003) Antibody-dependent enhancement of virus infection and disease. Viral Immunol 16: 69-86.
51. Uchida I, Sekizaki T, Hashimoto K & Terakado N (1985) Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J Gen Microbiol 131: 363-367.
52. Verma A, Wagner L, Stibitz S, Nguyen N, Guerengomba F & Burns DL (2008) Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay. Clin Vaccine Immunol 15: 1737-1741.
53. Verma A, Ngundi MM, Meade BD, De Pascallis R, Elkins KL & Burns DL (2009) Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin Vaccine Immunol 16: 1405-1412.
54. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M & Montecucco C (1998) Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Bioph Res Co 248: 706-711.
55. Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, Little SF, Andrews GP, Dorough G, Taylor RK & Keler T (2006) Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 74: 5840-5847.
56. Watson LE, Kuo S, Katki K, Dang T, Park SK, Dostal DE, Tang W-J, Leppla SH & Frankel AE (2007) Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One 5: e466.
57. Weiser JN, Bae D, Fasching C, Scamurra RW, Ratner AJ & Janoff EN (2003) Antibody-enhanced pneumococcal adherence requires IgA1 protease. P Natl Acad Sci USA 100: 4215-4220.
58. Weiss S, Kobiler D, Levy H, Marcus H, Pass A, Rothschild N & Altboum Z (2006) Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun 74: 394-398.
59. Young JAT & Collier RJ (2007) Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 76: 243-265.
60. 3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem Bioph Res Co 341: 1164-1171.